LOGIN  |  REGISTER
Amneal Pharmaceuticals
C4 Therapeutics

NeuroOne® Medical Technologies to Report Third Quarter Fiscal Year 2023 Financial Results and Provide a Corporate Update on August 14

August 08, 2023 | Last Trade: US$1.11 0.02 -1.77

EDEN PRAIRIE, Minn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its third quarter 2023 ended June 30, 2023 and provide a corporate update on August 14, 2023 at 4:30 PM Eastern Time.

Conference Call and Webcast Information:

Monday, August 14, 2023 – 4:30 PM Eastern Time

Participant Dial-In:
800-267-6316 / +1 203-518-9783
Conference ID (required for entry): NEURO

Live Webcast: 
Join here.

Phone Replay:
877-660-6853 / 201-612-7415
Available through August 28, 2023

Webcast Replay:
Available for 12 months

About NeuroOne

NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com

Contact:

800-631-4030
This email address is being protected from spambots. You need JavaScript enabled to view it.


Chimerix

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB